Cancer immunotherapy side effect study pulled before it began
NCT ID NCT06521762
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This study was designed to test whether the drug etrasimod (VELSIPITY) could help reduce the need for steroids in cancer patients who develop diarrhea and colon inflammation from immune checkpoint inhibitors. It planned to enroll about 0 participants with advanced cancer who had moderate to severe symptoms. However, the trial was withdrawn before any patients were enrolled, so no data was collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-RELATED DIARRHEA AND COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Etrasimod (also called VELSIPITY) taken as a 2 mg oral tablet daily, plus corticosteroids
What this could lead to
If it had worked, this could have pointed toward a way to reduce steroid use and shorten treatment breaks for cancer patients with severe diarrhea and colitis caused by immunotherapy.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It was a small early-stage study, and the approach may not have proven better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.